Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway (Q38320884)

2 September 2017

title

Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway (English)

1 reference

2 September 2017

main subject

protein ubiquitination

1 reference

6

Ruiwen Zhang

1 reference

2 September 2017

4

Elizabeth R Rayburn

1 reference

2 September 2017

2

Hui Wang

1 reference

2 September 2017

Zhuo Zhang

1

1 reference

2 September 2017

Mao Li

series ordinal

3

1 reference

2 September 2017

Sudhir Agrawal

series ordinal

5

1 reference

2 September 2017

language of work or name

English

0 references

publication date

1 November 2005

1 reference

2 September 2017

1 reference

2 September 2017

volume

24

1 reference

2 September 2017

issue

48

1 reference

2 September 2017

page(s)

7238-7247

1 reference

Transcription of dbpA, a Y box binding protein, is positively regulated by E2F1: implications in hepatocarcinogenesis

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208814

MDM2 is a central node in the p53 pathway: 12 years and counting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208814

Regulation of E2F through ubiquitin-proteasome-dependent degradation: stabilization by the pRB tumor suppressor protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208814

Mdm2-dependent ubiquitination and degradation of the insulin-like growth factor 1 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208814

Overexpression of E2F1 associated with LOH at RB locus and hyperphosphorylation of RB in non-small cell lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208814

Aberrant regulation of survivin by the RB/E2F family of proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208814

MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208814

An alternative splice form of Mdm2 induces p53-independent cell growth and tumorigenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208814

Sibling rivalry in the E2F family

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208814

Mdm2: A regulator of cell growth and death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208814

Novel antisense anti-MDM2 mixed-backbone oligonucleotides: proof of principle, in vitro and in vivo activities, and mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208814

Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208814

p53-independent activities of MDM2 and their relevance to cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208814

Growth factor-mediated induction of HDM2 positively regulates hypoxia-inducible factor 1alpha expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208814

7 January 2021

Myc-mediated proliferation and lymphomagenesis, but not apoptosis, are compromised by E2f1 loss.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208814

7 January 2021

Life and death decisions by E2F-1.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208814

7 January 2021

Mapping of the p53 and mdm-2 interaction domains

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208814

7 January 2021

Differential regulation of E2F1, DP1, and the E2F1/DP1 complex by ARF.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208814

7 January 2021

Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208814

7 January 2021

Mdm2 association with p53 targets its ubiquitination

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208814

7 January 2021

Transcription factor E2F-1 acts as a growth-promoting factor and is associated with adverse prognosis in non-small cell lung carcinomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208814

7 January 2021

RB regulates the stability and the apoptotic function of p53 via MDM2

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208814

7 January 2021

MDM2 promotes p21waf1/cip1 proteasomal turnover independently of ubiquitylation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208814

7 January 2021

Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208814

7 January 2021

Estrogen receptor-dependent proteasomal degradation of the glucocorticoid receptor is coupled to an increase in mdm2 protein expression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208814

7 January 2021

Identification of a cellular transcription factor involved in E1A trans-activation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208814

7 January 2021

The yin and yang of E2F-1: balancing life and death

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208814

7 January 2021

Application of comparative functional genomics to identify best-fit mouse models to study human cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208814

7 January 2021

Mono- versus polyubiquitination: differential control of p53 fate by Mdm2.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208814

7 January 2021

Genomic organisation of the human MDM2 oncogene and relationship to its alternatively spliced mRNAs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208814

7 January 2021

Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208814

7 January 2021

E2F-7: a distinctive E2F family member with an unusual organization of DNA-binding domains

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208814

7 January 2021

ACTR/AIB1 functions as an E2F1 coactivator to promote breast cancer cell proliferation and antiestrogen resistance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208814

7 January 2021

Interaction between ubiquitin-protein ligase SCFSKP2 and E2F-1 underlies the regulation of E2F-1 degradation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208814

7 January 2021

Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208814

7 January 2021

The RING domain of Mdm2 mediates histone ubiquitylation and transcriptional repression.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208814

7 January 2021

The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208814

7 January 2021

Evolving intricacies and implications of E2F1 regulation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208814

7 January 2021

Up-regulation of transcriptional factor E2F1 in papillary and anaplastic thyroid cancers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208814

7 January 2021

A novel mitochondrial protein DIP mediates E2F1-induced apoptosis independently of p53.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208814

7 January 2021

p53-independent role of MDM2 in TGF-beta1 resistance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208814

7 January 2021

Anti-tumor efficacy of a novel antisense anti-MDM2 mixed-backbone oligonucleotide in human colon cancer models: p53-dependent and p53-independent mechanisms.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208814

7 January 2021

Chemosensitization and radiosensitization of human cancer by antisense anti-MDM2 oligonucleotides: in vitro and in vivo activities and mechanisms

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208814

7 January 2021

Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208814

7 January 2021

Inactivating E2f1 reverts apoptosis resistance and cancer sensitivity in Trp53-deficient mice.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208814

7 January 2021

Expression of transcription factor E2F-1 in pancreatic ductal carcinoma: an immunohistochemical study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208814

7 January 2021

MDM2 oncogene as a novel target for human cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208814

7 January 2021

MDM2 is a negative regulator of p21WAF1/CIP1, independent of p53.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208814

7 January 2021

Radiosensitization by antisense anti-MDM2 mixed-backbone oligonucleotide in in vitro and in vivo human cancer models

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208814

7 January 2021

Identifiers

DOI

10.1038/SJ.ONC.1208814

1 reference

Dimensions Publication ID

2 September 2017

1039411058

0 references

1 reference